Both in Pharmaceuticals
Upstream Bio vs Akebia Therapeutics
Over the past year UPB returned −86.8% and AKBA returned −68.0%; their daily moves had a correlation of 0.22.
UPB −86.8% AKBA −68.0%Growth of $1, one year, split-adjusted
| Metric | UPB | AKBA |
|---|---|---|
| Price | $3.41 | $0.7065 |
| Market cap | $186.8M | $195.8M |
| Today | +4.28% | −4.81% |
| 1 month | −32.3% | −18.9% |
| 6 months | −63.7% | −49.5% |
| Year to date | −87.4% | −56.1% |
| 1 year | −85.9% | −66.4% |
| Revenue growth (YoY) | −17.5% | −21.4% |
| Gross margin | 100.0% | 78.8% |
| Net margin | −5136.1% | −18.1% |
| P/E (TTM) | — | — |
| Price / sales | 59.1× | 0.9× |
| Net cash | $261.3M | $106.0M |
| Dividend yield | — | — |
| Volatility (60d) | 83.4% | 73.8% |
| Short % of float | 13.2% | 8.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).